• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

早期乳腺癌的剂量强度：社区实践经验。

Dose intensity in early-stage breast cancer: a community practice experience.

机构信息

Fairfax Northern Virginia Hematology Oncology, Fairfax, VA.

出版信息

J Oncol Pract. 2009 Nov;5(6):287-90. doi: 10.1200/JOP.091036.

DOI:10.1200/JOP.091036
PMID:21479074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2869188/
Abstract

Although nodal status, grade, size, and receptor status play roles in determining breast cancer prognosis, there is increasing evidence that maintaining dose intensity of adjuvant chemotherapy increases disease-free survival rate.

摘要

虽然淋巴结状态、分级、大小和受体状态在确定乳腺癌预后方面起作用，但越来越多的证据表明维持辅助化疗的剂量强度可以提高无病生存率。

相似文献

1
Dose intensity in early-stage breast cancer: a community practice experience.早期乳腺癌的剂量强度：社区实践经验。
J Oncol Pract. 2009 Nov;5(6):287-90. doi: 10.1200/JOP.091036.
2
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.曲妥珠单抗辅助治疗后 HER2 阳性乳腺癌患者的奈拉替尼治疗（ExteNET）：一项多中心、随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2016 Mar;17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.
5
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.乳腺癌不同肿瘤生物学亚组之间病理解剖因素的预后相关性差异：辅助 SUCCESS A 研究的结果。
Breast. 2019 Apr;44:81-89. doi: 10.1016/j.breast.2018.12.008. Epub 2018 Dec 20.
6
Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.日常实践中辅助化疗的剂量变化和方案调整会影响台湾I-II期及可手术III期乳腺癌患者的生存情况。
Breast. 2008 Dec;17(6):646-53. doi: 10.1016/j.breast.2008.05.006. Epub 2008 Jul 1.
7
The influence of young age on outcome in early stage breast cancer.年轻对早期乳腺癌预后的影响。
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33. doi: 10.1016/0360-3016(94)90515-0.
8
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.用于指导早期乳腺癌女性辅助化疗决策的基因表达谱分析：基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.
9
Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.在日常临床实践中，相对剂量强度作为乳腺癌辅助化疗质量和预后的替代指标。
Eur J Cancer. 2017 Jul;79:152-157. doi: 10.1016/j.ejca.2017.04.001. Epub 2017 May 8.
10
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.氟尿嘧啶和剂量密集化疗在早期乳腺癌辅助治疗中的应用：一项开放标签、2×2 析因、随机、3 期临床试验。
Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.

引用本文的文献

1
Clinicopathological Factors and Interleukin-6 Levels Associated With Low Relative Dose Intensity in Women With Breast Cancer Receiving First-Line Chemotherapy.接受一线化疗的乳腺癌女性中与低相对剂量强度相关的临床病理因素及白细胞介素-6水平
World J Oncol. 2024 Dec;15(6):942-949. doi: 10.14740/wjon1954. Epub 2024 Oct 30.
2
Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer.蒽环类药物-环磷酰胺诱导的口腔黏膜炎与随后多西他赛用于围手术期乳腺癌治疗的相关性
Support Care Cancer. 2024 Jul 13;32(8):513. doi: 10.1007/s00520-024-08733-7.
3
Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer.地塞米松系统给药剂量对乳腺癌患者多西他赛所致口腔黏膜炎的影响。
Sci Rep. 2023 Jun 22;13(1):10169. doi: 10.1038/s41598-023-37285-9.
4
Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment.地塞米松全身给药对含蒽环类药物方案治疗乳腺癌引起的口腔黏膜炎的影响。
Sci Rep. 2022 Jul 22;12(1):12587. doi: 10.1038/s41598-022-16935-4.
5
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.培非格司亭与来格司亭用于预防II-IV期乳腺癌患者化疗引起的中性粒细胞减少症的成本-效用分析
Front Pharmacol. 2017 Sep 13;8:614. doi: 10.3389/fphar.2017.00614. eCollection 2017.

本文引用的文献

1
Undertreatment of cancer patients with chemotherapy is a global concern.癌症患者化疗治疗不足是一个全球关注的问题。
J Oncol Pract. 2008 May;4(3):114-5. doi: 10.1200/JOP.0831502.
2
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.接受化疗的成年癌症患者中性粒细胞减少事件的风险及发生时间：一项全国肿瘤学实践前瞻性研究的结果
J Natl Compr Canc Netw. 2008 Feb;6(2):109-18. doi: 10.6004/jnccn.2008.0012.
3
Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.美国国立综合癌症网络关于在癌症化疗中使用髓系生长因子的指南：证据综述
J Natl Compr Canc Netw. 2005 Jul;3(4):557-71. doi: 10.6004/jnccn.2005.0031.
4
Relative dose intensity: improving cancer treatment and outcomes.相对剂量强度：改善癌症治疗及预后
Oncol Nurs Forum. 2005 Jul 1;32(4):757-64. doi: 10.1188/05.ONF.757-764.
5
Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices.临床肿瘤学实践中化疗引起的中性粒细胞减少症的管理方案。
Cancer Nurs. 2005 Jan-Feb;28(1):62-9. doi: 10.1097/00002820-200501000-00009.
6
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.可手术乳腺癌辅助性CMF随机研究的30年随访：队列研究
BMJ. 2005 Jan 29;330(7485):217. doi: 10.1136/bmj.38314.622095.8F. Epub 2005 Jan 13.
7
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.辅助性乳腺癌化疗中低剂量强度的发生率及预测因素：一项全国性社区实践研究。
J Clin Oncol. 2003 Dec 15;21(24):4524-31. doi: 10.1200/JCO.2003.05.002.
8
Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.为早期乳腺癌女性提供辅助化疗：当前的治疗模式
Cancer. 2001 Sep 15;92(6):1354-67. doi: 10.1002/1097-0142(20010915)92:6<1354::aid-cncr1458>3.0.co;2-p.
9
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.中危非霍奇金淋巴瘤患者的化疗给药模式
Oncology (Williston Park). 2001 Oct;15(10):1296-306; discussion 1310-1, 1314.
10
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.辅助性环磷酰胺、甲氨蝶呤和氟尿嘧啶用于治疗淋巴结阳性乳腺癌：20年随访结果
N Engl J Med. 1995 Apr 6;332(14):901-6. doi: 10.1056/NEJM199504063321401.